Cargando…

Biologics in Paediatric Crohn's Disease

Crohn's disease affects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course than in adults and has a greater impact on quality of life. Therapy in children must take account of a different set of risks for toxicity compared to adults, but also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gouldthorpe, Oliver, Catto-Smith, Anthony G., Alex, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226300/ https://www.ncbi.nlm.nih.gov/pubmed/22144993 http://dx.doi.org/10.1155/2011/287574

Ejemplares similares

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
por: Gouldthorpe, Oliver, et al.
Publicado: (2013)

Interaction of Crohn's Disease Susceptibility Genes in an Australian Paediatric Cohort
por: Wagner, Josef, et al.
Publicado: (2010)

Enteral Nutrition in Crohn's Disease: An Underused Therapy
por: Kansal, S., et al.
Publicado: (2013)

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease
por: Szymanska, Edyta, et al.
Publicado: (2015)

Identification and Characterisation of Pseudomonas 16S Ribosomal DNA from Ileal Biopsies of Children with Crohn's Disease
por: Wagner, Josef, et al.
Publicado: (2008)

Economic implications of biological therapy for Crohn's disease
por: Petryszyn, Paweł W., et al.
Publicado: (2015)

Disseminated Tuberculosis Mimicking as Crohn's Disease in a Paediatric Patient
por: Feenstra, Elizabeth, et al.
Publicado: (2023)

Biologics: how far can they go in Crohn’s disease?
por: Dunleavy, Katie A, et al.
Publicado: (2022)

A review of magnetic resonance enterography based Crohn’s disease activity indices in paediatric patients
por: Herman, Roma B., et al.
Publicado: (2022)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Biologic therapies for Crohn’s disease: optimising the old and maximising the new
por: Samaan, Mark, et al.
Publicado: (2019)

Biologics and surgical outcomes in Crohn’s disease: is there a direct relationship?
por: Quaresma, Abel Botelho, et al.
Publicado: (2020)

Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn’s Disease
por: Agrawal, Gaurav, et al.
Publicado: (2020)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
por: Koh, Seong-Joon, et al.
Publicado: (2023)

A Review of the Impact of Biologics on Surgical Complications in Crohn's Disease
por: Chang, Melissa I., et al.
Publicado: (2015)

Vital Signs in Palliative Care: A Scoping Review
por: Power, Jenny, et al.
Publicado: (2023)

Challenges in Managing Paediatric Crohn’s Disease With Crohn’s Disease Exclusion Diet (CDED): The First Single-Center Study in the United Arab Emirates
por: Alsarhan, Ali, et al.
Publicado: (2023)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2017)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
por: Ooi, Choon Jin, et al.
Publicado: (2019)

Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era"
por: Lightner, Amy L., et al.
Publicado: (2017)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

CROHN'S DISEASE
Publicado: (1972)

Crohn's Disease
Publicado: (1973)

Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease
por: Logan, Michael, et al.
Publicado: (2022)

Dietary Therapy to Improve Nutrition and Gut Health in Paediatric Crohn’s Disease; A Feasibility Study
por: Allen, Stephen J., et al.
Publicado: (2022)

Resection Leads to Less Recurrence Than Strictureplasty in a Paediatric Population with Obstructive Crohn's Disease
por: Bamford, Richard, et al.
Publicado: (2014)

Role of Multiparametric Intestinal Ultrasound in the Evaluation of Response to Biologic Therapy in Adults with Crohn’s Disease
por: Puca, Pierluigi, et al.
Publicado: (2022)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Crohn’s disease in women
por: Plavšić, Ivana, et al.
Publicado: (2013)

Management of Crohn's disease
por: Kammermeier, Jochen, et al.
Publicado: (2016)

A review of the therapeutic management of Crohn’s disease
por: Kumar, Aditi, et al.
Publicado: (2022)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Serum anti-glycan antibodies in paediatric-onset Crohn's disease: association with disease phenotype and diagnostic accuracy
por: Sładek, Małgorzata, et al.
Publicado: (2014)

Plasma elafin, cathelicidin, and α-defensins are increased in paediatric inflammatory Crohn’s disease and reflect disease location
por: Wędrychowicz, Andrzej, et al.
Publicado: (2021)

Pathogenesis of Crohn's disease
por: Boyapati, Ray, et al.
Publicado: (2015)

Clinical usefulness of the Mucosal Inflammation Noninvasive Index in newly diagnosed paediatric Crohn’s disease patients
por: Herman, Roma B., et al.
Publicado: (2021)

Dietary Habit Modifications in Paediatric Patients after One Year of Treatment with the Crohn’s Disease Exclusion Diet
por: Martín-Masot, Rafael, et al.
Publicado: (2023)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ej2engj66jgcktgml81kdeu055